We invite you to join us for this web-based conference to add to the lively discussion!

NETWORK OF T32 PROGRAMS IN PEDIATRIC CLINICAL PHARMACOLOGY

PLEASE JOIN US FOR:
PEDIARTIC CLINICAL PHARMACOLOGY JOURNAL CLUB
ONCOLOGY EDITION
December 17, 2013 at Noon EST
(Login Instructions below)

THE TOPIC:
EXPLORING THE CONTROVERSY SURROUNDING GENETIC PREDICTORS OF CISPLATIN-INDUCED OTOTOXICITY

In 2009, Ross and colleagues in Vancouver British Columbia genotyped 220 drug-metabolism genes in pediatric oncology patients and found variants in TPMT and COMT that were linked to cisplatin mediated ototoxicity. Recently Yang et al., attempted to replicate these findings at St Jude's but did not find an association between TPMT/COMT variants and ototoxicity. Around the same time, the British Columbia group attempted to replicate their initial findings, and could not with COMT, but did with TPMT and found an additional transporter ABCC3 with variants that may predict ototoxicity. Clinical Pharmacology and Therapeutics printed both of these opposing articles together in 2013, and just in their most recent issue have also published commentary by Dr. Ratain on this controversy. We will discuss these articles below and the data that has sparked the debate:

4. Yang JJ et al. The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-Induced

We invite you to join us for this web-based conference to add to the lively discussion!

Presenters:

Dr. Michael Ferguson of Indiana University
Dr. Behzad Bidadi of Mayo Clinic
Dr. Mark Ratain of University of Chicago
Dr. Jun Yang of St. Jude’s Children’s

LOGIN INSTRUCTIONS
Connecting to the Web Meeting Room:
To join the Webinar, please click the following link:
http://fuze.me/22220083
If asked to enter a meeting number, enter 22220083
For Audio Dial: 1-855-346-3893
Meeting Number: 22220083 #